Acumen, JCR Pharma Join To Develop Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimers
Collaboration Announcement: Acumen Pharmaceuticals has entered into a collaboration and license agreement with JCR Pharmaceuticals to develop an Enhanced Brain Delivery therapy targeting Alzheimer's disease, utilizing JCR's BBB-penetrating technology.
Clinical Trial Progress: Acumen is currently conducting a Phase 2 trial for its lead program, sabirnetug, with topline results expected in late 2026, while JCR stands to receive upfront payments and royalties from any resulting products.
Trade with 70% Backtested Accuracy
Analyst Views on ABOS
About ABOS
About the author
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Wall Street Analysts Adjust Ratings
- Acumen Price Target Raised: BTIG raised Acumen Pharmaceuticals' price target from $4 to $7, with analyst Thomas Shrader maintaining a Buy rating, indicating confidence in the company's growth potential despite a closing price of $2.08 on Monday.
- Exelixis Target Price Increase: HC Wainwright & Co. raised the price target for Exelixis from $49 to $52, with analyst Robert Burns maintaining a Buy rating, reflecting optimism about its market performance, closing at $43.61 on Monday.
- Baker Hughes Price Target Upgraded: BMO Capital increased Baker Hughes' price target from $55 to $65, with analyst Phillip Jungwirth maintaining an Outperform rating, suggesting a positive outlook on its future performance, closing at $56.29 on Monday.
- Brown & Brown Price Target Cut: B of A Securities lowered the price target for Brown & Brown from $94 to $90, with analyst Joshua Shanker maintaining a Neutral rating, indicating a cautious stance on the company's short-term performance, closing at $79.62 on Monday.
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
Healthcare Stocks Surge in After-Hours Trading: KYMR, OCUL, POAI Lead the Gains
Kymera Therapeutics Inc.: The company's shares surged 9.58% to $73.00 in after-hours trading, driven by anticipation of results from the BroADen Phase 1b clinical trial for its oral STAT6 degrader for atopic dermatitis, set to be announced on December 8.
Ocular Therapeutix Inc.: Shares increased by 11.29% to $14.00 after hours, following recent progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, despite no new updates on Friday.
Predictive Oncology Inc.: The stock jumped 13.62% to $4.84 after hours, rebounding from a significant decline during the day, as the company regained compliance with Nasdaq's minimum stockholders' equity requirement.
Acumen Pharmaceuticals Inc.: Shares rose 3.23% to $1.92 after hours, following a presentation at the CTAD conference on improved delivery of Alzheimer's treatment antibodies, indicating positive long-term development prospects.
Acumen Pharmaceuticals Announces Financial Results and Business Highlights for Q3 2025
Financial Overview: Acumen Pharmaceuticals reported a cash balance of $136.1 million as of September 30, 2025, which is expected to support its clinical and operational activities into early 2027. The company experienced a decrease in both research and development expenses and net loss compared to the previous year.
Clinical Trials Update: The company anticipates non-clinical data for its Enhanced Brain Delivery (EBD™) program in early 2026 and expects topline results from the Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) for early Alzheimer's disease in late 2026.
Leadership Changes: Acumen appointed George Golumbeski, Ph.D., as the new Chairman of its Board of Directors, bringing over 30 years of biopharmaceutical experience to the company.
Product Development Focus: Acumen is focused on advancing sabirnetug, a monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs), which are implicated in Alzheimer's disease, and is also exploring a subcutaneous formulation using Halozyme's drug delivery technology.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Wall Street Analysts Adjust Ratings
- Acumen Price Target Raised: BTIG raised Acumen Pharmaceuticals' price target from $4 to $7, with analyst Thomas Shrader maintaining a Buy rating, indicating confidence in the company's growth potential despite a closing price of $2.08 on Monday.
- Exelixis Target Price Increase: HC Wainwright & Co. raised the price target for Exelixis from $49 to $52, with analyst Robert Burns maintaining a Buy rating, reflecting optimism about its market performance, closing at $43.61 on Monday.
- Baker Hughes Price Target Upgraded: BMO Capital increased Baker Hughes' price target from $55 to $65, with analyst Phillip Jungwirth maintaining an Outperform rating, suggesting a positive outlook on its future performance, closing at $56.29 on Monday.
- Brown & Brown Price Target Cut: B of A Securities lowered the price target for Brown & Brown from $94 to $90, with analyst Joshua Shanker maintaining a Neutral rating, indicating a cautious stance on the company's short-term performance, closing at $79.62 on Monday.
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
Healthcare Stocks Surge in After-Hours Trading: KYMR, OCUL, POAI Lead the Gains
Kymera Therapeutics Inc.: The company's shares surged 9.58% to $73.00 in after-hours trading, driven by anticipation of results from the BroADen Phase 1b clinical trial for its oral STAT6 degrader for atopic dermatitis, set to be announced on December 8.
Ocular Therapeutix Inc.: Shares increased by 11.29% to $14.00 after hours, following recent progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, despite no new updates on Friday.
Predictive Oncology Inc.: The stock jumped 13.62% to $4.84 after hours, rebounding from a significant decline during the day, as the company regained compliance with Nasdaq's minimum stockholders' equity requirement.
Acumen Pharmaceuticals Inc.: Shares rose 3.23% to $1.92 after hours, following a presentation at the CTAD conference on improved delivery of Alzheimer's treatment antibodies, indicating positive long-term development prospects.
Acumen Pharmaceuticals Announces Financial Results and Business Highlights for Q3 2025
Financial Overview: Acumen Pharmaceuticals reported a cash balance of $136.1 million as of September 30, 2025, which is expected to support its clinical and operational activities into early 2027. The company experienced a decrease in both research and development expenses and net loss compared to the previous year.
Clinical Trials Update: The company anticipates non-clinical data for its Enhanced Brain Delivery (EBD™) program in early 2026 and expects topline results from the Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) for early Alzheimer's disease in late 2026.
Leadership Changes: Acumen appointed George Golumbeski, Ph.D., as the new Chairman of its Board of Directors, bringing over 30 years of biopharmaceutical experience to the company.
Product Development Focus: Acumen is focused on advancing sabirnetug, a monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs), which are implicated in Alzheimer's disease, and is also exploring a subcutaneous formulation using Halozyme's drug delivery technology.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
